Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug Submission For HT-KIT, Treatment For Cancer Patients
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics has announced that the FDA has accepted its pre-investigational new drug submission for HT-KIT, a treatment for cancer patients. The drug has received Orphan Drug Designation from the FDA for its mRNA Frame Shifting Cancer Therapeutic. Hoth intends to initially target mast cell neoplasms with HT-KIT, a rare and aggressive cancer with a poor prognosis.
September 11, 2023 | 2:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hoth Therapeutics' HT-KIT, a treatment for cancer patients, has been accepted by the FDA for pre-investigational new drug submission. This could potentially boost the company's stock in the short term.
The FDA's acceptance of Hoth Therapeutics' pre-investigational new drug submission for HT-KIT is a significant regulatory milestone for the company. This could potentially lead to increased investor confidence and a short-term boost in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100